These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33259937)

  • 1. Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.
    Patel M; Finlay DB; Glass M
    Cell Signal; 2021 Feb; 78():109865. PubMed ID: 33259937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists.
    Wouters E; Walraed J; Banister SD; Stove CP
    Biochem Pharmacol; 2019 Nov; 169():113623. PubMed ID: 31472128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
    Manning JJ; Green HM; Glass M; Finlay DB
    Neuropharmacology; 2021 Aug; 193():108611. PubMed ID: 34000272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.
    Mallipeddi S; Janero DR; Zvonok N; Makriyannis A
    Biochem Pharmacol; 2017 Mar; 128():1-11. PubMed ID: 27890725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
    Alam RM; Keating JJ
    Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
    Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
    Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB
    Patel M; Grimsey NL; Banister SD; Finlay DB; Glass M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01157. PubMed ID: 38018694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Selectivity at Cannabinoid Receptors.
    Priestley R; Glass M; Kendall D
    Adv Pharmacol; 2017; 80():207-221. PubMed ID: 28826535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
    Chung EY; Cha HJ; Min HK; Yun J
    Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
    Finlay DB; Manning JJ; Ibsen MS; Macdonald CE; Patel M; Javitch JA; Banister SD; Glass M
    ACS Chem Neurosci; 2019 Oct; 10(10):4350-4360. PubMed ID: 31513380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.
    Hindson SA; Andrews RC; Danson MJ; van der Kamp MW; Manley AE; Sutcliffe OB; Haines TSF; Freeman TP; Scott J; Husbands SM; Blagbrough IS; Anderson JLR; Carbery DR; Pudney CR
    FEBS J; 2023 Jun; 290(12):3243-3257. PubMed ID: 36708234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
    Nimczick M; Decker M
    ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.
    Bosier B; Muccioli GG; Hermans E; Lambert DM
    Biochem Pharmacol; 2010 Jul; 80(1):1-12. PubMed ID: 20206137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias.
    Sharma R; Singh S; Whiting ZM; Molitor M; Vernall AJ; Grimsey NL
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
    Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
    Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
    Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
    Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.